Skip to main content
Log in

Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors

  • consensus report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

The Austrian Society for Hematology and Medical Oncology (OeGHO) aimed to define a clear position on the importance of molecular diagnostics in solid tumors. This position covers the following four points: the indication for the assessment of a molecular profile has to be given by the treating medical oncologist depending on the course of the patient’s disease; the requirement that the molecular profile might lead to a therapeutic intervention in the individual patient; quality control of the molecular analysis through proficiency testing and/or accreditation of the method used; and adherence to patient’s data safety according to data protection regulation. The present position paper does not cover the topic of germline mutations and other assessments in human genetics. Due to the fact that clinically relevant information on germline mutations may appear during the diagnostic processing we strongly recommend thorough patient education and documentation of patient consent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.

    Article  CAS  PubMed  Google Scholar 

  2. Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895–902. https://doi.org/10.1093/annonc/mdy263.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wolfgang Eisterer.

Ethics declarations

Conflict of interest

G. Prager, A. Gerger, G. Höfler, G. Webersinke, H. Rumpold, T. Winder, R. Bartsch, M. Preusser, and W. Eisterer declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prager, G., Gerger, A., Höfler, G. et al. Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors. memo 13, 450–452 (2020). https://doi.org/10.1007/s12254-020-00662-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-020-00662-5

Keywords

Navigation